Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$20.48M
TTM
Current Assets
Q3 2023
Current Liabilities
Q3 2023
Current Ratio
23.99%
Q3 2023
Total Assets
Q3 2023
Total Liabilities
Q3 2023
Book Value
-$20.05M
Q3 2023
Cash
Q3 2023
P/E
-0.00001533
Nov 27, 2024 EST
Free Cash Flow
-$17.99M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $75.00K $75.00K $182.2K $7.819K $200.0K $0.00 $140.0K $280.0K $460.0K $300.0K $70.00K $130.0K $20.00K $10.00K $200.0K $0.00 $0.00
YoY Change -100.0% 0.0% -58.84% 2230.59% -96.09% -100.0% -50.0% -39.13% 53.33% 328.57% -46.15% 550.0% 100.0% -95.0%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $75.00K $75.00K $182.2K $7.819K $200.0K $0.00 $140.0K $280.0K $460.0K $300.0K $70.00K $130.0K $20.00K $10.00K $200.0K $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Selling, General & Admin $10.69M $20.45M $14.85M $24.71M $26.48M $3.990M $1.610M $3.170M $3.350M $2.210M $2.720M $2.470M $2.220M $2.210M $2.290M $2.410M $1.920M $2.030M $2.910M $1.490M $1.940M $1.490M $1.970M
YoY Change -47.71% 37.7% -39.9% -6.68% 563.66% 147.83% -49.21% -5.37% 51.58% -18.75% 10.12% 11.26% 0.45% -3.49% -4.98% 25.52% -5.42% -30.24% 95.3% -23.2% 30.2% -24.37% 0.0%
% of Gross Profit
Research & Development $23.73M $22.90M $14.59M $26.30M $20.49M $16.40M $8.986M $5.842M $3.339M $2.087M $2.566M $3.720M $2.640M $2.350M $1.760M $1.210M $1.570M $1.420M $1.150M $790.0K $370.0K $480.0K $480.0K
YoY Change 3.62% 56.95% -44.52% 28.36% 24.95% 82.48% 53.82% 74.98% 60.0% -18.69% -31.02% 40.92% 12.34% 33.52% 45.45% -22.93% 10.56% 23.48% 45.57% 113.51% -22.92% 0.0% 0.0%
% of Gross Profit
Depreciation & Amortization $77.00K $114.0K $68.00K $87.00K $216.0K $39.00K $8.000K $5.000K $18.28K $2.583K $2.386K $2.798K $130.0K $110.0K $100.0K $170.0K $40.00K $40.00K $30.00K $40.00K $20.00K $20.00K $20.00K
YoY Change -32.46% 67.65% -21.84% -59.72% 453.85% 387.5% 60.0% -72.64% 607.51% 8.26% -14.72% -97.85% 18.18% 10.0% -41.18% 325.0% 0.0% 33.33% -25.0% 100.0% 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $34.42M $22.90M $33.46M $50.56M $47.57M $20.39M $9.840M $6.284M $3.339M $2.087M $2.566M $3.720M $4.990M $4.560M $4.060M $3.620M $3.490M $3.450M $4.050M $2.280M $2.310M $1.970M $2.450M
YoY Change 50.31% -31.55% -33.82% 6.29% 133.28% 107.22% 56.59% 88.22% 60.0% -18.69% -31.02% -25.44% 9.43% 12.32% 12.15% 3.72% 1.16% -14.81% 77.63% -1.3% 17.26% -19.59% 0.0%
Operating Profit -$34.42M -$66.02M -$33.46M -$50.56M -$47.57M -$20.39M -$9.840M -$6.284M -$9.148M -$4.651M -$5.412M -$7.919M
YoY Change -47.86% 97.33% -33.82% 6.29% 133.28% 107.22% 56.59% -31.31% 96.71% -14.06% -31.66%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Interest Expense -$1.723M -$1.249M -$1.120M -$320.0K $500.0K -$74.00 -$533.00 -$2.767K -$77.44K -$119.1K -$127.1K -$88.12K -$8.180M -$1.440M -$1.000M $70.00K $100.0K $50.00K $30.00K $70.00K $20.00K $30.00K $0.00
YoY Change 37.95% 11.52% 250.0% -164.0% -675775.68% -86.12% -80.74% -96.43% -34.97% -6.28% 44.2% -98.92% 468.06% 44.0% -1528.57% -30.0% 100.0% 66.67% -57.14% 250.0% -33.33%
% of Operating Profit
Other Income/Expense, Net -$1.646M -$709.0K -$1.122M -$319.0K $502.0K -$824.0K -$7.000K $10.00K $0.00 -$1.720M $0.00 $130.0K $0.00 $0.00 $0.00 $0.00 $0.00 $140.0K $190.0K $0.00 $0.00
YoY Change 132.16% -36.81% 251.72% -163.55% -160.92% 11671.43% -170.0% -100.0% -100.0% -100.0% -26.32%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Pretax Income -$36.07M -$66.73M -$34.58M -$50.87M -$47.06M -$21.21M -$9.847M -$18.06M -$9.225M -$6.120M -$5.070M -$7.270M -$13.38M -$5.730M -$4.600M -$3.250M -$3.320M -$2.980M -$3.730M -$2.070M -$1.940M -$1.880M -$2.440M
YoY Change -45.95% 92.98% -32.03% 8.1% 121.85% 115.44% -45.49% 95.81% 50.74% 20.71% -30.26% -45.67% 133.51% 24.57% 41.54% -2.11% 11.41% -20.11% 80.19% 6.7% 3.19% -22.95% 0.0%
Income Tax $0.00 $0.00 $0.00 $0.00 $122.0K -$640.0K -$680.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$36.07M -$66.73M -$34.58M -$50.87M -$47.19M -$21.21M -$9.847M -$6.406M -$9.225M -$6.123M -$5.066M -$7.269M -$13.38M -$5.727M -$4.601M -$3.252M -$3.315M -$2.979M -$3.727M -$2.778M -$3.022M -$1.880M -$2.440M
YoY Change -45.95% 92.98% -32.03% 7.82% 122.42% 115.44% 53.72% -30.56% 50.68% 20.85% -30.3% -45.69% 133.7% 24.46% 41.51% -1.91% 11.28% -20.07% 34.16% -8.07% 60.73% -22.95% 108.73%
Net Earnings / Revenue -13129.33% -8541.33% -5062.44% -78303.39% -2533.07% -9559.65% -2045.31% -1000.32% -1083.9% -4735.55% -2291.48% -18634.76% -27780.04% -1510.85%
Basic Earnings Per Share -$16.65 -$38.15
Diluted Earnings Per Share -$16.65 -$953.7K -$861.9K -$1.337M -$1.455M -$4.259M -$8.108M -$25.08M -$34.19M -$87.43M -$126.8M -$242.3M -$1.338B -$573.0M -$460.0M -$325.0M -$332.0M -$298.0M -$373.0M -$207.0M -$402.9M -$476.8M -$770.2M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Cash & Short-Term Investments $19.21M $42.27M $24.67M $56.28M $48.61M $24.05M $810.0K $3.330M $6.110M $1.600M $2.000M $3.610M $8.030M $1.430M $6.180M $660.0K $1.170M $4.230M $4.140M $2.420M $3.670M $10.00K $10.00K
YoY Change -54.56% 71.33% -56.17% 15.78% 102.12% 2869.14% -75.68% -45.5% 281.88% -20.0% -44.6% -55.04% 461.54% -76.86% 836.36% -43.59% -72.34% 2.17% 71.07% -34.06% 36600.0% 0.0%
Cash & Equivalents $19.21M $42.27M $24.67M $22.49M $48.61M $24.05M $810.0K $3.330M $6.110M $1.600M $2.000M $3.610M $8.030M $380.0K $5.680M $410.0K $320.0K $290.0K $190.0K $320.0K $800.0K $10.00K $10.00K
Short-Term Investments $33.78M $0.00 $1.050M $500.0K $250.0K $850.0K $3.940M $3.950M $2.100M $2.870M $2.870M
Other Short-Term Assets $922.0K $1.212M $1.230M $1.430M $1.740M $460.0K $170.0K $400.0K $1.070M $1.920M $1.550M $1.450M $1.300M $1.160M $180.0K $110.0K $140.0K $160.0K $90.00K $190.0K $60.00K $20.00K $20.00K
YoY Change -23.93% -1.46% -13.99% -17.82% 278.26% 170.59% -57.5% -62.62% -44.27% 23.87% 6.9% 11.54% 12.07% 544.44% 63.64% -21.43% -12.5% 77.78% -52.63% 216.67% 200.0% 0.0%
Inventory
Prepaid Expenses
Receivables $0.00 $40.00K $40.00K $80.00K $80.00K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $20.13M $43.48M $25.89M $57.71M $50.34M $24.51M $980.0K $3.730M $7.220M $3.520M $3.550M $5.060M $9.330M $2.590M $6.360M $760.0K $1.310M $4.390M $4.230M $2.610M $3.800M $30.00K $30.00K
YoY Change -53.71% 67.94% -55.14% 14.64% 105.39% 2401.02% -73.73% -48.34% 105.11% -0.85% -29.84% -45.77% 260.23% -59.28% 736.84% -41.98% -70.16% 3.78% 62.07% -31.32% 12566.67% 0.0%
Property, Plant & Equipment $994.0K $1.659M $550.0K $1.130M $250.0K $280.0K $90.00K $190.0K $220.0K $0.00 $10.00K $0.00 $0.00 $10.00K $10.00K $10.00K $10.00K $30.00K $50.00K $80.00K $80.00K $80.00K $80.00K
YoY Change -40.08% 201.64% -51.33% 352.0% -10.71% 211.11% -52.63% -13.64% -100.0% -100.0% 0.0% 0.0% 0.0% -66.67% -40.0% -37.5% 0.0% 0.0% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $250.0K $250.0K $990.0K $990.0K
YoY Change -100.0% 0.0% 0.0%
Other Assets $0.00 $30.00K $110.0K $130.0K $50.00K $50.00K $10.00K $10.00K $10.00K $10.00K $10.00K $640.0K $1.070M $10.00K $10.00K $10.00K $10.00K $10.00K $10.00K $10.00K $10.00K
YoY Change -100.0% -72.73% -15.38% 0.0% 400.0% 0.0% 0.0% 0.0% 0.0% -98.44% -40.19% 10600.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Total Long-Term Assets $994.0K $1.659M $590.0K $1.240M $380.0K $270.0K $8.250M $15.82M $26.11M $3.580M $3.400M $3.540M $4.580M $4.530M $4.280M $2.560M $2.230M $1.720M $980.0K $660.0K $1.430M $240.0K $240.0K
YoY Change -40.08% 181.19% -52.42% 226.32% 40.74% -96.73% -47.85% -39.41% 629.33% 5.29% -3.95% -22.71% 1.1% 5.84% 67.19% 14.8% 29.65% 75.51% 48.48% -53.85% 495.83% 0.0%
Total Assets $21.12M $45.14M $26.48M $58.95M $50.72M $24.78M $9.230M $19.55M $33.33M $7.100M $6.950M $8.600M $13.91M $7.120M $10.64M $3.320M $3.540M $6.110M $5.210M $3.270M $5.230M $270.0K $270.0K
YoY Change
Accounts Payable $3.020M $1.379M $480.0K $1.870M $750.0K $1.530M $90.00K $230.0K $900.0K $640.0K $590.0K $560.0K $560.0K $980.0K $370.0K $110.0K $80.00K $220.0K $70.00K $60.00K $80.00K $170.0K $170.0K
YoY Change 119.0% 187.29% -74.33% 149.33% -50.98% 1600.0% -60.87% -74.44% 40.63% 8.47% 5.36% 0.0% -42.86% 164.86% 236.36% 37.5% -63.64% 214.29% 16.67% -25.0% -52.94% 0.0%
Accrued Expenses $3.511M $4.853M $3.020M $5.150M $6.940M $1.890M $260.0K $410.0K $920.0K $390.0K $370.0K $510.0K $580.0K $360.0K $310.0K $380.0K $330.0K $180.0K $290.0K $260.0K $300.0K $270.0K $270.0K
YoY Change -27.65% 60.7% -41.36% -25.79% 267.2% 626.92% -36.59% -55.43% 135.9% 5.41% -27.45% -12.07% 61.11% 16.13% -18.42% 15.15% 83.33% -37.93% 11.54% -13.33% 11.11% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $2.190M $2.200M $2.200M $2.190M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% -0.45% 0.0% 0.46%
Long-Term Debt Due $3.980M $0.00 $5.240M $4.340M
YoY Change -100.0% 20.74%
Total Short-Term Liabilities $23.09M $9.955M $9.840M $11.81M $7.810M $3.420M $370.0K $780.0K $1.830M $3.210M $3.160M $3.270M $3.330M $1.330M $680.0K $500.0K $450.0K $430.0K $390.0K $320.0K $380.0K $440.0K $440.0K
YoY Change 131.95% 1.17% -16.68% 51.22% 128.36% 824.32% -52.56% -57.38% -42.99% 1.58% -3.36% -1.8% 150.38% 95.59% 36.0% 11.11% 4.65% 10.26% 21.88% -15.79% -13.64% 0.0%
Long-Term Debt $8.557M $12.00M $6.380M $10.50M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $10.00K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -28.67% 88.03% -39.24% -100.0%
Other Long-Term Liabilities $135.0K $804.0K $30.00K $430.0K $1.060M $2.620M $100.0K $100.0K $340.0K $810.0K $2.600M $120.0K $120.0K $130.0K $130.0K $90.00K $90.00K $90.00K $70.00K $50.00K $50.00K
YoY Change -83.21% 2580.0% -93.02% -59.54% 2520.0% 0.0% -70.59% -58.02% -68.85% 2066.67% 0.0% -7.69% 0.0% 44.44% 0.0% 0.0% 28.57% 40.0% 0.0%
Total Long-Term Liabilities $8.692M $12.80M $6.410M $10.93M $0.00 $0.00 $1.060M $2.620M $100.0K $100.0K $340.0K $810.0K $2.600M $130.0K $120.0K $130.0K $130.0K $90.00K $90.00K $90.00K $70.00K $50.00K $50.00K
YoY Change -32.09% 99.69% -41.35% -100.0% -59.54% 2520.0% 0.0% -70.59% -58.02% -68.85% 1900.0% 8.33% -7.69% 0.0% 44.44% 0.0% 0.0% 28.57% 40.0% 0.0%
Total Liabilities $31.78M $22.76M $16.25M $22.73M $7.810M $3.420M $4.670M $7.320M $5.840M $3.310M $3.500M $4.080M $5.930M $1.450M $810.0K $630.0K $580.0K $520.0K $480.0K $410.0K $440.0K $480.0K $480.0K
YoY Change 39.67% 40.03% -28.51% 191.04% 128.36% -26.77% -36.2% 25.34% 76.44% -5.43% -14.22% -31.2% 308.97% 79.01% 28.57% 8.62% 11.54% 8.33% 17.07% -6.82% -8.33% 0.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Basic Shares Outstanding 2.166M 1.749M
Diluted Shares Outstanding 2.166M 1.749M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $314.00

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2012-11-23. The firm is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The firm is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The firm also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Industry: Biological Products, (No Diagnostic Substances) Peers: Ampio Pharmaceuticals, Inc. TREX WIND-DOWN, INC. Avenir Wellness Solutions, Inc. PLx Pharma Winddown Corp. Evofem Biosciences, Inc. JOHNSON & JOHNSON KALA BIO, Inc. OTONOMY, INC. TITAN PHARMACEUTICALS INC